A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Part of paid clinical trials in Morgantown, West Virginia.

Sponsor
Ascendis Pharma A/S
Study ID
NCT07345494
Status
Recruiting
Apply to this trial

Conditions

  • Hypoparathyroidism

Eligibility Criteria

Sex
FEMALE
Age
15 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.

Key Dates

Start date
Feb 18, 2026
Status verified
Feb 2026
Primary completion
Jan 31, 2036
Completion
Jan 31, 2036

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Palopegteriparatide
    Pregnant women exposed to palopegteriparatide during pregnancy

Primary Outcome Measure

The number of fetuses as reported by HCP [ Time Frame: 21 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ascendis Investigational SiteMorgantownWest Virginia26508-

Find similar trials in Morgantown, WV

By research site
Ascendis Investigational Site· Morgantown, WV

Related Studies